

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Sumitomo Chemical Co., Ltd.</u> (Last) (First) (Middle) 27-1, SHINKAWA 2-CHOME CHUO-KU (Street) TOKYO M0 104-8260 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Urovant Sciences Ltd. [UROV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) See Footnote (1)
	3. Date of Earliest Transaction (Month/Day/Year) 02/19/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/19/2020		P		12,873	A	\$13.08	22,872,886	I	See Footnote ⁽¹⁾
Common Stock	02/19/2020		P		15,165	A	\$13.08	22,888,051	I	See Footnote ⁽¹⁾
Common Stock	02/19/2020		P		75,212	A	\$13.08	22,963,263	I	See Footnote ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person * <u>Sumitomo Chemical Co., Ltd.</u> (Last) (First) (Middle) 27-1, SHINKAWA 2-CHOME CHUO-KU (Street) TOKYO M0 104-8260 (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person *		
Dainippon Sumitomo Pharma Co Ltd		
(Last)	(First)	(Middle)
6-8 DOSHOMACHI 2-CHOME CHUO-KU		
(Street)		
OSAKA	M0	541-0045
(City) (State) (Zip)		
1. Name and Address of Reporting Person *		
Sumitovant Biopharma Ltd.		
(Last)	(First)	(Middle)
11-12 ST. JAMES'S SQUARE SUITE 1 3RD FLOOR		
(Street)		
LONDON	X0	SW1Y 4LB
(City) (State) (Zip)		

Explanation of Responses:

1. Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.

[Sumitomo Chemical Co., Ltd.](#)
 By: [Yoshiaki Oda, Managing Executive /s/ Yoshiaki Oda](#) 02/21/2020
[Sumitomo Dainippon Pharma Co., Ltd. By: Yumi Sato, Senior /s/ Yumi Sato](#) 02/21/2020
[Sumitovant Biopharma Ltd. By: Marianne L. Romeo, Authorized /s/ Marianne L. Romeo](#) 02/21/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.